Experimental studies further demonstrate that FLZD ameliorates hepatic inflammation and lipid accumulation in NAFLD models by inhibiting TLR4/MyD88/TRAF6 signaling pathway activation, consequently downregulating IL-2, IL-6, and TNF-α expression while reducing serum TC levels [176]. The gene discussed is MYD88; the disease is metabolic dysfunction-associated steatotic liver disease.